Lipigon attracts SEK 16.6 Million in new investment round to fight cardiovascular disease

Umeå-based Lipigon Pharmaceuticals has attracted SEK 16.6 Million in a new share issue that will help it get nearer to its goal of reducing the number of global deaths caused by cardiovascular disease.
“We are extremely proud our new shares issue was oversubscribed, particularly during the ongoing Coronavirus pandemic when many investors are feeling more cautious. It is an indication of the level of belief in us,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Lipigon signs major new deal with Shanghai-listed HitGen

Umeå-based Lipigon Pharmaceuticals AB has signed a major new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases.
“We want to create effective treatments and contribute to a better quality of life for patients,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Lipigon signs new deal in billion dollar market

Umeå-based Lipigon Pharmaceuticals has signed a new deal and taken over the patent portfolio for a number of drug candidates that could help treat cardiovascular diseases.
“The market in treatments for various blood fat disorders amounts to several billion dollars. This is a very important opportunity for us,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Lipigon recruits new talent after multi-million SEK deal

Life science company Lipigon Pharmaceuticals has recruited two new members of staff following the signing of a multi-million SEK agreement for its gene therapy project with listed Nordic company CombiGene.
The new appointments will bring additional knowledge and skills to the Umeå-based company that will help it reach project milestones in the years ahead.
“This agreement allows us to grow, which is great for us and for Umeå,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Lipigon signs multi-million gene therapy deal

Life science company Lipigon Pharmaceuticals has signed an agreement for its gene therapy project with listed company CombiGene.
“If everything goes well this agreement could potentially be worth millions. But it also enables us to develop our business in the short term, not least because we can now employ highly competent staff in Umeå,” says Stefan K Nilsson, CEO of Lipigon.

Read more

Lipigon signs target validation agreement with Secarna Pharma

The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases. 

Read more